OPKO Health, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
OPKO Health, Inc. (OPK) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 706.22 thousand shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-02-26
- OPKO Health, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2022-12-31 was 2.04M shares.
- OPKO Health, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2022-09-30 was 216.04K shares.
- OPKO Health, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2022-06-30 was 242.73K shares.
- OPKO Health, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2025 was 706.22K shares, a 21.85% decline from fiscal 2024.
- OPKO Health, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 903.64K shares, a 1.99% increase from fiscal 2023.
- OPKO Health, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2023 was 886.01K shares, a 64.58% decline from fiscal 2022.
- OPKO Health, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2022 was 2.50M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | 706.22K shares 10-K · filed 2026-02-26 | ||||
| 2024-12-31 | 903.64K shares 10-K · filed 2025-03-03 | ||||
| 2023-12-31 | 886.01K shares 10-K · filed 2024-03-01 | ||||
| 2022-12-31 | 2.04M shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | 2.26M shares derived: sum of 2 quarters · filed 2023-11-06 | 2.50M shares derived: sum of 3 quarters · filed 2023-11-06 | 2.50M shares 10-K · filed 2023-02-27 | |
| 2022-09-30 | 216.04K shares 10-Q · filed 2023-11-06 | 458.76K shares derived: sum of 2 quarters · filed 2023-11-06 | 458.76K shares 10-Q · filed 2023-11-06 | ||
| 2022-06-30 | 242.73K shares 10-Q · filed 2023-08-03 | 242.73K shares 10-Q · filed 2023-08-03 | |||
| 2021-12-31 | 0.00 shares 10-K · filed 2024-03-01 | 2.59M shares 10-K · filed 2022-03-01 | |||
| 2020-12-31 | 1.00M shares 10-K · filed 2021-02-18 | ||||
| 2019-12-31 | 1.44M shares 10-K · filed 2020-03-02 | ||||
| 2018-12-31 | 1.53M shares 10-K · filed 2019-03-01 | ||||
| 2017-12-31 | 2.74M shares 8-K · filed 2019-01-29 | ||||
| 2016-12-31 | 1.47M shares 10-K · filed 2017-03-01 | ||||
| 2015-12-31 | 710.25K shares 10-K · filed 2016-02-29 | ||||
| 2014-12-31 | 727.13K shares 10-K · filed 2015-02-27 | ||||
| 2013-12-31 | 488.50K shares 10-K · filed 2014-03-03 | ||||
| 2012-12-31 | -327.75K shares 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |